ArticleInvestigative ophthalmology & visual science2025
SLC6A6-Mediated Taurine Uptake Sustains Corneal Epithelial Stem/Progenitor Cell Function to Counteract Age-Related Dysfunction.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to elucidate the role of SLC6A6-mediated taurine transport in maintaining corneal limbal stem/progenitor cell (LSPC) function and its implications for age-associated corneal wound healing. Methods: Corneal amino acid profiles from C57BL/6J mice were analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS). SLC6A6 expression patterns were mapped using single-cell RNA sequencing, quantitative PCR, and immunofluorescence. Pharmacological inhibition of SLC6A6 with guanidinoethyl sulfonate (GES) was applied in corneal wound healing models and murine corneal epithelial stem/progenitor (TKE2) cells. Transcriptomic profiling, RNA/protein analyses, and functional assays were performed in GES-treated TKE2 cells. Aged mice with corneal epithelium scraping received topical taurine supplementation (25 mg/mL, 5 times/day), and the corneas were collected for immunofluorescence staining. Moreover, TKE2 cells were treated with GES along with the Notch1 agonist valproic acid (VPA), or they were treated with taurine along with the Notch1 inhibitor GSI-IX (DAPT). Results: The cornea exhibited high taurine concentrations, with its transporter SLC6A6 predominantly localized in LSPCs (limbal stem cells, transient amplifying cells, and basal cells) and displaying age-dependent expression patterns. SLC6A6 inhibition delayed corneal wound healing, triggered senescence pathway activation and pluripotency suppression, and downregulated stemness markers (BCAM, p63, KRT14, Wnt4) and proliferative markers (Ki67), which recapitulated key features of corneal aging. This functional decline was reversed through topical taurine supplementation. Moreover, VPA effectively reversed the inhibitory effect of GES, whereas DAPT attenuated the effect of taurine, indicating involvement of the Notch1 signaling pathway in taurine-induced LSPC maintenance. Conclusions: SLC6A6-driven taurine uptake critically regulates LSPC homeostasis, presenting a therapeutic strategy for age-related corneal disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.